Leaders in abdominal cancer and cardiology join Myka Labs advisory board

Myka Labs announced today the addition of two key figures to its Clinical Advisory Board.

Dr. Ivo Boskoski is Assistant Professor of Gastroenterology at the Università Cattolica & Fondazione Policlinico Universitario Agostino Gemelli IRCCS Catholic University in Rome, Italy. Dr. Boskoski is a global leader in advanced endoscopic procedures and has authored over 150 papers including holding senior authorship on a number of important recent papers in the fields of gastroenterology and cancer, spanning topics from pancreatic insulinoma to malignant biliary obstruction to pancreatitis to metabolism. He is a key contributor in the European Society of Gastrointestinal Endoscopy’s assessment of opportunities and risks around artificial intelligence. Dr. Boskoski is a member of the American College of Gastroenterology, the European Society of Gastrointestinal Endoscopy and the American Society of Gastrointestinal Endoscopy, and is a member of the Advisory Board of the Italian Society of Young Gastroenterologists. He received his medical degree from the University of Perugia and holds a Ph.D. in experimental surgery from the Università Cattolica. At Myka Labs, he will play a key role in the development of Conflux for endoscopic bypass of malignancy-associated obstruction as well as broader corporate priorities around precision surgery.

Dr. Jacob Mishell is Director of the Structure Heart Program for Kaiser Permanente Northern California, a practicing interventional cardiologist with the Permanente Medical Group, and Assistant Clinical Professor of Medicine in the Division of Cardiology at the University of California, San Francisco. He is a member of the Society for Cardiovascular Angiography and Interventions; a Fellow of the American College of Cardiology; and a member of the American College of Physicians. He is heavily involved in clinical research, with leadership roles on major clinical studies in areas including transcatheter tricuspid valve replacement, transcatheter mitral valve repair and patent foramen ovale closure for stroke. He received his MD from the University of Rochster and completed his internship and residency at Johns Hopkins. At Myka Labs, Dr. Mishell is central to new initiatives inside the company to apply its industry-leading navigation systems technology in new areas, including structural heart.

Two global leaders in patient care join Myka Labs Advisory Board

Longtime Dana Farber Cancer Institute CEO Dr. Edward Benz and Dr. Richard Isaacs, former CEO of Kaiser Permanente, bring extraordinary knowledge and experience

Dr. Edward Benz. Trained as a clinical hematologist, Dr. Benz is a fellow of the American College of Physicians. His research centers on the molecular basis and genetics of inherited blood disorders like thalassemia. Dr. Benz has served as president of the American Society of Hematology, the Association of American Cancer Institutes, the American Society for Clinical Investigation, the American Clinical and Climatological Association, and the Friends of the National Institutes of Nursing Research. From 2000 to 2016, Dr. Benz served as President and CEO of Dana-Farber Cancer Institute, director and principal investigator of Dana-Farber/Harvard Cancer Center, and a member of the Governing Board of Dana-Farber/Children’s Cancer Center. At Myka Labs, he will guide the company’s current and future initiatives in cancer, including its pipeline expansion beyond the pancreatic and other abdominal cancers where its advanced intraoperative imaging technology is positioned to markedly extend patient lives.

Dr. Richard Isaacs. Dr. Isaacs is Dean of the College of Medicine at California Northstate University. Previously, Dr. Isaacs held the position of CEO at The Permanente Medical Group, the largest medical group in the nation. He also served as the president of The Mid-Atlantic Permanente Medical Group. In these roles, he led 12,000 physicians and 45,000 staff members, overseeing the medical care of 5.4 million Kaiser Permanente members on both the west and east coasts. Dr. Isaacs has been named among Modern Healthcare’s 50 most influential physician leaders and 100 most influential healthcare leaders. Dr. Isaacs is trained in otolaryngology and head and neck surgery, specializing in skull base, head and neck oncologic/microvascular surgery. At Myka Labs, he will provide essential insight on the company’s product initiatives and corporate strategy, including how the company’s technologically advanced products can have a foundational role in future advances in integrated health care delivery.